Vanda Pharmaceuticals (VNDA) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $6.40 +0.16%
Revenue Growth %: +17.5%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
CRMT, PKE, HELE, More
Revenue Growth %: +17.5%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
CRMT, PKE, HELE, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $7.4 million versus the consensus estimate of $8.07 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA grants Vanda rare pediatric disease tag for CMT2S therapy
- LG Energy 2q Oper Profit 113.3b Won, Est. 210.66b Won - Bloomberg
- Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
